![Merck and Co Inc](/common/images/company/NY_MRK.png)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vacci... Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States. Show more
Symposia will highlight work to overcome HIV-related stigma and discuss the evolving state of HIV treatment and prevention Merck (NYSE: MRK), known as MSD outside of the United States and Canada...
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret™, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration...
Acquisition delivers industry-leading portfolio, scientific and research capabilities, for enhanced customer benefits Merck Animal Health, known as MSD Animal Health outside of the United States...
Elanco Completes Sale of Aqua Business PR Newswire GREENFIELD, Ind., July 9, 2024 Transaction concentrates Elanco's focus on significant value creation opportunities and accelerates deleveraging...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Orion Corporation (“Orion”) today announced that notice has been provided of the mutual exercise of an option to...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00...
If approved by the European Commission, WINREVAIR will be the first activin signaling inhibitor therapy for PAH in Europe, offering a new treatment option for certain adults with this rare...
CAPVAXIVE (V116) recommended for all adults age 65 and older and for adults 19 to 64 with certain risk conditions, and for those over 65 previously vaccinated with other pneumococcal vaccines...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.4 | -1.87251306858 | 128.17 | 129.03 | 122.37 | 7645378 | 125.77007442 | CS |
4 | -5.31 | -4.05096124504 | 131.08 | 134.63 | 120.87 | 9971074 | 126.719223 | CS |
12 | -5.86 | -4.4518726734 | 131.63 | 134.63 | 120.87 | 8423444 | 128.15230793 | CS |
26 | 6.55 | 5.49404462339 | 119.22 | 134.63 | 117.27 | 8356010 | 126.56726424 | CS |
52 | 15.5 | 14.056407001 | 110.27 | 134.63 | 99.14 | 7947432 | 117.09719252 | CS |
156 | 49.31 | 64.4912372482 | 76.46 | 134.63 | 70.89 | 9683380 | 97.47703699 | CS |
260 | 44.09 | 53.9789422135 | 81.68 | 134.63 | 65.25 | 9895133 | 90.20170635 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.